

## 2024 Multi-site Gram-Negative Surveillance Initiative (MuGSI) Healthcare-Associated Infections Community Interface (HAIC) Case Report

**NOTE:** Enter all dates as mm/dd/yyyy

Form Approved OMB No. 0920-0978

PATIENT'S	S NAME:				PHO	ONE NO.:	
ADDRESS	:					MRN:	
ADDRESS	TYPE:		HOSPITAL: _				
		Pat	ient Identifier inf	formation is not trai	nsmitted to CDC	· <b>-</b>	
DEMOG							1
1. STATE:	2a. COUNTY:		2b	o. PLANNING REGION:			3. STATE ID:
4a. LABOF	RATORY ID WHE	RE INCIDENT SPECIME	N IDENTIFIED:		4b. FACILITY ID WI	HERE PATIENT	TREATED:
5. DATE O	F BIRTH:	7. SEX AT BIRTH:	8a. ETH	INIC ORIGIN:	8b. RACE: (Check al	ll that apply)	
6. AGE: O Male O Female O Unknown C Days O Mos O Yrs		O Female	O Not I O Unkr	anic or Latino Hispanic or Latino nown	Alaska Native Asian		☐ Native Hawaiian or Other Pacific Islander ☐ White ☐ Unknown
9a. DATE OF INCIDENT SPECIMEN COLLECTION (DISC):  10. ORGANISM  Carbapenem- Escherichia co  Klebsiella pro Klebsiella oxy		Resistant Enterobacterales (CRE)  coli  neumoniae  cytoca  Exten  produ  Esch  Kleb		ducing Énterobacterales (ESBL-E) cherichia coli ebsiella pneumoniae		☐ Carbapenem-Resistant A. baumannii (CRAB) ☐ Invasive Escherichia coli (iEC) (not CRE or ESBL-E)	
		☐ Klebsiella ae ☐ Enterobacte		□ KI	ebsiella oxytoca		
Blood Bone Bronch (CRAB of CSF Interna  12. LOCAT O OUTP. Facility ID: O Emel O Clinic O Dialy O Surg O Obse Clinic O Othe	rgency room c/Doctor's office vsis center ery ervational/ cal decision unit er outpatient	Mu Pe Pe Pe Joi Sp Tra  EN COLLECTION: O INPATIENT Facility ID: O CU O OR O Radiology O Other inpatient	ritoneal fluid ricardial fluid eural fluid nt/synovial fluid utum (CRAB only, com cheal aspirate (CRAB  OLTCF Facility ID: OLTACH Facility ID: OAutopsy OOther (Specify): OUnknown	13. WHERE W DAY BEFO O Private ro O LTCF Facility II O Hospital Facility II Was the pat from this ho	(CRAB only) Other LRT site (specific (CRAB only, complete (CRAB only, co	ecify): lete Q23c) erile site (specify)  CATED ON THE  O LTA Fac: O Hor O Inca O Oth	carcerated ser (specify):
IF YES	S, DATE OF ADMIS	·				Yes ON	lo O Unknown
		AN ICU IN THE 7 DAYS  MISSION:			lo O Unknown		
-	THE PATIENT IN	AN ICU ON THE DAY C			R IN THE 6 DAYS AF	TER THE DISC?	
		OMISSION:	OR U Dat	te unknown			
		is collection of information			ponse, including the ti	me for reviewing	instructions, searching
existing da	ta sources, gatheri	ng and maintaining the o	lata needed, and com	npleting and reviewing t	he collection of inform	nation. An agency	y may not conduct or nd comments regarding this

burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30329; ATTN: PRA (0920-XXXX).

16. PATIENT OUTCOME:							
	<u>-</u>	OR	IF SURVIVED, D	DISCHARGED	TO:		
I ( ) Dieu	Date unknown		O Private resi	dence	O Othe	er (specify):	
OUnknown	Left against medical advice (AMA)		O LTCF, Facilit	ty ID:			
	_		O LTACH, Faci	ility ID:	O Unki	nown	
DATE OF DEATH:	OR Date unknown		C LIACH, raci	y iD			
17a. TYPES OF INFECTION AS	SSOCIATED WITH CULTURE(S): (Chec	k all that appl	y) O None	O Colo	nized OUnkr	nown	
Abscess, not skin	☐ Decubitus/pressure ulcer	Pneum	nonia (CRAB cases,	complete O2	23c) $\square$ Skin a	bscess	
AV fistula/graft infection			ephritis complete		Surgio	al incision infection	
☐ Bacteremia	Endocarditis	Sepsis				al site infection (internal)	
Bursitis	Epidural abscess	Urose				atic wound v tract infection	
Catheter site infection (C	CVC) Meningitis Osteomyelitis	Septic Septic				plete 22a–22c)	
Chronic ulcer/wound	Peritonitis	Septic			☐ Other	(specify):	
(not decubitus)	Tentonius						
17b. RECURRENT UTI:			17c. WAS THE P	ATIENT TRE	ATED FOR THE	MUGSI ORGANISM?	
	Unknown				OUnknown		
18. UNDERLYING CONDITION	NS: (Check all that apply) O None	Oun	known				
CHRONIC LUNG DISEASE	IMMUNOCOMPROMISED CON			GIC CONDITI	ON	SKIN CONDITION	
Cystic fibrosis	HIV infection		☐ Cereb			Burn	
Chronic pulmonary dise				ic cognitive d	leficit	Decubitus/pressure ulcer	
CHRONIC METABOLIC DISE	ASE Primary immunodeficiency Transplant, hematopoietic		☐ Deme		izure disorder	Surgical wound Other chronic ulcer or	
Diabetes mellitus	Transplant solid array.	. Sterri ceri		ole sclerosis	izure disorder	chronic wound	
☐ With chronic complicat	ions		Neuro			Other (specify):	
CARDIOVASCULAR DISEASE	<u></u>		= '	son's disease			
CVA/Stroke/TIA Congenital heart disease	LIVER DISEASE		☐ Other	(specify):		OTHER	
Congestive heart failure	L Chronic liver disease		<u> </u>			Connective tissue disease	
Myocardial infarction	Ascites		PLEGIAS/F	ΡΔ ΡΔΙ ΥΚΙΚ		Obesity or morbid obesity	
Peripheral vascular disea	Cirrhosis  Hepatic encephalopathy		Hemip			☐ Pregnant	
(PVD)	Variceal bleeding		☐ Parapl	legia		MuGSI CONDITIONS	
GASTROINTESTINAL DISEAS	Hepatitis C		☐ Quadr	riplegia		Urinary tract problems/	
☐ Diverticular disease☐ Inflammatory bowel dise	Treated, in SVR		RENAL DIS	SEASE		Premature birth	
Peptic ulcer disease	Current, chronic			ic kidney dise		Spina bifida	
Short gut syndrome	<u>MA</u> LIGNANCY			st serum crea	tinine:	·	
☐ Malignancy, hematologic mg/DL ☐ Malignancy, solid organ (non-metastatic) ☐ Unknown or not done							
	Malignancy, solid organ (n Malignancy, solid organ (n		tic) 🔲 Unkr	nown or not d	lone		
	Malignaticy, solid organ (ii	netastatic)					
19. SUBSTANCE USE				AL	COHOL ABUSE:		
SMOKING: (Check all that ap	· //		☐ Marijuana	_	Yes O No	Ounknown	
	☐ Unknown ☐ E-nicotine de	elivery syste	m				
OTHER SUBSTANCES: (Check	all that apply) O None O Unknowr	n					
			OUD/ ABUSE	MC	DE OF DELIVERY	(Check all that apply)	
Marijuana, cannabinoio	(other than smoking)		DUD or abuse		Skin popping	Non-IDU Unknown	
Opioid, DEA schedule I	•		DUD or abuse		Skin popping	□ Non-IDU □ Unknown	
			DUD or abuse		Skin popping	□ Non-IDU □ Unknown	
_			Skin popping  Skin popping	Non-IDU Unknown			
Opioid, NOS		l —					
Cocaine			DUD or abuse		Skin popping	□ Non-IDU □ Unknown	
Methamphetamine		l <u> </u>	DUD or abuse		Skin popping	□ Non-IDU □ Unknown	
Other (specify):			2020. 45450		Skin popping	□ Non-IDU □ Unknown	
☐ Unknown substance			DUD or abuse	□IDU	Skin popping	□ Non-IDU □ Unknown	
DURING THE CURRENT HOS	PITALIZATION, DID THE PATIENT RECEIV	/E MEDICAT	ION ASSISTED TR	EATMENT (M	AT) FOR OPIOID (	JSE DISORDER?	
I	(patient not hospitalized or did not have						

20. RISK FACTORS: (Check all that apply)				
WAS INCIDENT SPECIMEN COLLECTED 3 OR MORE CALENDAR DAYS AFTER HOSPITAL ADMISSION?	<b>O</b> Yes	ONo		
PREVIOUS HOSPITALIZATION IN THE YEAR BEFORE DISC	Oyes	ONo	OUnknown	
IF YES, DATE OF DISCHARGE CLOSEST TO DISC: OR,				Facility ID:
OVERNIGHT STAY IN LTCF IN THE YEAR BEFORE DISC:	<b>O</b> Yes	ONo	OUnknown	Facility ID:
OVERNIGHT STAY IN LTACH IN THE YEAR BEFORE DISC:	<b>O</b> Yes	ONo	OUnknown	Facility ID:
SURGERY IN THE YEAR BEFORE DISC:	O Yes	ONo	OUnknown	
CURRENT CHRONIC DIALYSIS:  IF YES, TYPE: O Hemodialysis O Peritoneal O Unknown	O Yes	O No	OUnknown	
IF HEMODIALYSIS, TYPE OF VASCULAR ACCESS: O AV fistula/graft O Hemodialysis centra	al line (	) Unkno	wn	
CENTRAL LINE IN PLACE ON THE DISC (UP TO THE TIME OF COLLECTION),				
OR AT ANY TIME IN THE 2 CALENDAR DAYS BEFORE DISC:	O Yes	ONo	OUnknown	
☐ Check here if central line in place for > 2 calendar days  URINARY CATHETER IN PLACE ON THE DISC (UP TO THE TIME OF COLLECTION),				
OR AT ANY TIME IN THE 2 CALENDAR DAYS BEFORE DISC:	O Yes	ONo	OUnknown	
IF YES, CHECK ALL THAT APPLY:  Indwelling Urethral Catheter  Condom Catheter				
Suprapubic Catheter Other (specify):				
ANY OTHER INDWELLING DEVICE IN PLACE ON THE DISC UP TO THE TIME OF COLLECTION), OR AT ANY TIME IN THE 2 CALENDAR DAYS BEFORE DISC:	OYes	ONo	OUnknown	
IF YES, CHECK ALL THAT APPLY: ☐ ET/NT Tube ☐ NG Tube ☐ Nephrostomy Tube				
☐ Gastrostomy Tube ☐ Tracheostomy ☐ Other (specify):				
PATIENT TRAVELED INTERNATIONALLY IN THE YEAR BEFORE DISC:	O Yes	O No	O Unknown	
COUNTRY(IES):				
PATIENT HOSPITALIZED WHILE VISITING COUNTRY(IES) ABOVE:	O Yes	O No	O Unknown	
21a. WEIGHT: 21b. HEIGHT:				21c. BMI:
lbsoz. ORkg	OR	_ cm	Unknown	Unknown
Complete questions 22a-22c for all MuGSI cases from urine cultures or where UTI or pyelone	phritis is n	narked i	n question 17a	•
22a. WAS THE URINE COLLECTED THROUGH AN INDWELLING URETHRAL CATHETER?	O Yes	ONo	OUnknown	
22b. RECORD THE COLONY COUNT:				
<b>22c. ASSOCIATED SIGNS AND SYMPTOMS:</b> Please indicate if any of the following symptoms were reported during the 5 day time period including the 2 calendar days after the DISC.	the 2 calend	dar days l	pefore through	
None	Symp	toms for	patients ≤ 1 ye	
Unknown Frequency		Apnea	□ Leti dia □ Vor	
☐ Costovertebral angle pain or tenderness ☐ Suprapubic tenderness ☐ Urgency	L 11	Bradycard	iia <b>Li</b> vor	niting
Complete questions 23a-23b ONLY for A. BAUMANNII cases:				
23a. DID THE PATIENT HAVE A SPUTUM CULTURE POSITIVE FOR CRAB IN THE 30 DAYS BEFORE THE DISC?	O Yes	Ono	OUnknown	O N/A
23b. RISK FACTORS PRIOR TO CRAB DISC: (Check all that apply)				
Non-invasive positive pressure ventilation (CPAP or BiPAP) at any time in the 7 calendar days	s before th	e DISC		
<ul><li>Nebulizer treatment at any time in the 7 calendar days before the DISC</li><li>Mechanical ventilation at any time in the 7 calendar days before the DISC</li></ul>				
None of the above				

Complete question 23c ONLY for	r A. BAUMANNII cases from LRT site cultures	s or for non-LRT cultures where	e pneumonia is mark	ed in question 17a.	
23c. CHEST RADIOLOGY FINE  Not done  No report available  Acute respiratory distress synce Air space density/opacity	☐ Ground glass opaciti ☐ Bronchopneumonia,	/pneumonia 🔲 Infiltrat	e $\square$	Nodules No evidence of pneumonia	
24a. IS ANTIMICROBIAL USE (	IV OR ORAL) IN THE 30 DAYS BEFORE TH	E DISC DOCUMENTED?	O Yes O No	O Unknown	
24b. IF YES, CHECK ALL ANTIN	MICROBIALS USED IN THE 30 DAYS BEFO	RE THE DISC: (Check all that o	apply)	Unknown	
Amikacin Amoxicillin Amoxicillin/clavulanic acid Ampicillin Ampicillin/sulbactam Azithromycin Aztreonam Cefadroxil Cefazolin Cefdinir Cefepime Cefiderocol Cefixime Cefoxitin Cefoxitin Cefoxitin Cefoxitin Cefoxitin Cefpodoxime Ceftaroline	Amoxicillin       □ Ceftazidime/avibactam       □ Fo         □ Amoxicillin/clavulanic acid       □ Ceftizoxime       □ Ge         □ Ampicillin       □ Ceftolozane/tazobactam       □ Im         □ Ampicillin/sulbactam       □ Ceftriaxone       □ Le         □ Azithromycin       □ Cefuroxime       □ Li         □ Aztreonam       □ Cephalexin       □ M.         □ Cefadroxil       □ Ciprofloxacin       □ M.         □ Cefazolin       □ Clarithromycin       □ M.         □ Cefolinir       □ Clindamycin       □ M.         □ Cefepime       □ Dalbavancin       □ Ni         □ Ceficiderocol       □ Daptomycin       □ Or         □ Cefixime       □ Delafloxacin       □ Or         □ Cefotaxime       □ Doripenem       □ Pe         □ Cefoxitin       □ Doxycycline       □ Pi         □ Cefpodoxime       □ Ertapenem       □ Pc		Rifaximin Tedizolid Telavancin Tigecycline Tobramycin Trimethoprim Trimethoprim/sulfamethoxazole Vancomycin IV PO Other (specify):  REMINDER: Any prior antimicrobial use that is not noted above should be documented in the other (specify) field.		
O Yes O No O Ur	A POSITIVE TEST(S) FOR SARS-CoV-2 (MC IN THE 90 DAYS BEFORE OR DAY OF THE hknown  DATES FOR POSITIVE TESTS IN THE 90 D  or Date unknown	DISC?	THE DISC:		
	IE YEAR BEFORE OR DAY OF DISC:	None or N/A			
26. WAS THE INCIDENT SPECI		O Yes	O No O Unknow		
	IMEN TESTED FOR CARBAPENEMASE GI	ENES? O Yes	O No O Laborato	ory not testing O Unknown	
27b. IF YES, WHAT TESTING METHOD WAS USED? (Check all that apply)  Non-Molecular Test Methods:    CarbaNP		Automated Molecu Carba-R Check Points MALDI-TOF MS	Check Points  MALDI-TOF MS  Next Generation Nucleic Acid Sequencing		
27c. IF TESTED, WHAT WAS TH	HE TESTING RESULT?				
Non-Molecular Test Results: O Positive O Indeterminate O Negative O Unknown	Molecular Test Results:  NDM KPC OXA (specify):	O Pos O	Neg O Ind Neg O Ind Neg O Ind	O Unk O Unk O Unk	
	VIM IMP Other carbapenemase gene (specify):	O Pos O	Neg O Ind Neg O Ind Neg O Ind	O Unk O Unk O Unk	

28a. WAS THE INCIDENT SPECIMEN TESTED FOR ESBL PRODUCTION OR OTHER  O Yes O No O Laboratory not testing O Unknown	BETA-LACTAMASE GENES?
28b. IF TESTED, WHAT TESTING METHOD WAS USED? (Check all that apply):	28c. IF TESTED, WHAT WAS THE RESULT?
☐ Broth Microdilution (ATI detection)	
☐ ESBL well	O Pos O Neg O Ind O Unk
☐ Expert rule (ATI flag)	O Pos O Neg O Ind O Unk
Unknown	O Pos O Neg O Ind O Unk
☐ Broth Microdilution (Manual)	O Pos O Neg O Ind O Unk
☐ Disk Diffusion	O Pos O Neg O Ind O Unk
☐ E-test	O Pos O Neg O Ind O Unk
Molecular test (specify):	O Pos O Neg O Ind O Unk
Gene variant (specify):	O Pos O Neg O Ind O Unk

Amikacin Amoxicillin/Clavulanate Ampicillin Ampicillin/Sulbactam Aztreonam	MIC or zone diameter	Interpretation	MIC or zone diameter	Interpretation	MIC or zone diameter	Interpretation
Amoxicillin/Clavulanate Ampicillin Ampicillin/Sulbactam Aztreonam						e.p.ctatio.
mpicillin mpicillin/Sulbactam ztreonam						
mpicillin/Sulbactam ztreonam						
ztreonam						
4 11						
efazolin						
efepime						
efiderocol						
efotaxime						
efoxitin						
eftazidime						
eftazidime/Avibactam						
eftolozane/Tazobactam						
eftriaxone						
ephalothin			1			
iprofloxacin						
olistin						
oripenem						
oxycycline						
ravacycline						
tapenem						
osfomycin						
entamicin						
nipenem						
nipenem-relebactam						
evofloxacin						
eropenem						
leropenem-vaborbactam						-
linocycline						
loxifloxacin						-
itrofurantoin						
madacycline						
iperacillin/Tazobactam						
lazomicin						
olymyxin B						
ifampin						
etracycline						
-						
gecycline						
obramycin rimethoprim-						
lfamethoxazole						
30a. WAS THE CASE FIRST IDENTIFIED THROUGH AN AUDIT?  Ores No		30b. CRF STATUS O Complete O Pending O Chart unavaila O Complete – pe	ble after 3 requests	30c. SO INITIALS:	30d. DATE OF	ABSTRACTION